

GLAND PHARMA LIMITED

April 29, 2024

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors (the "**Board**") of Gland Pharma Limited (the "**Company**") at its Meeting held today, i.e., Monday, April 29, 2024 has inter-alia considered and approved the appointment of Mr. Satnam Singh Loomba as Chief Operating Officer (COO) and Senior Management Personnel of the Company with effect from May 01, 2024.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in <u>Annexure-A</u> enclosed herewith.

The Board meeting commenced at 11:30 Hrs. IST and ended at 13:30 Hrs. IST.

This is for your information and records.

Yours truly, For Gland Pharma Limited

Sampath Kumar Pallerlamudi Company Secretary and Compliance Officer

Encl: As above

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax: +91-40-30510800



Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Mr. Satnam Singh Loomba

| SI. No | Particulars | Remarks |
|--------|---|--|
| 1 | Reason for change & Date of Change | Mr. Satnam Singh Loomba has been appointed as Chief Operating Officer (COO); a Senior Management Personnel of the Company, effective May 01, 2024 |
| 2 | Brief profile | Mr. Satnam Singh Loomba is a senior pharmaceutical and management professional with an extensive background in multi-cultural, global environments for pharmaceutical Operations & Business and proficient in several multifunctional departments. He has over 30 years of experience in API Operations & Development, Global Supply Planning & Operations in Manufacturing, Formulations, Global Material Sourcing, Corporate Strategic Business Planning, and Global Supply Chain for Global Markets. He has experience in managing operations in Formulations in Pharmaceuticals, Narcotics, Cosmetics, Food and Alternate medicine like Sterile Injectables, Infusions, Aerosol based Inhalers, Sprays, Lyophilized products, Insulin, Lozenges, etc. He has been instrumental in attaining accreditations from USFDA, MHRA, EDQM Cofepris, TGA, MCC, Health Canada, ANVISA, PMDA, KFDA. Before joining Gland, Satnam was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories. Mr. Loomba has done his Master of Business Administration from University Business School, Chandigarh. He is also a graduate in Chemical Engineering from Andhra University, Visakhapatnam. |
| 3 | Disclosure of relationships between director | NA |